Ceftolozane-tazobactam inhibited 96.3% of the 1,576 P. aeruginosa isolates deemed to be the probable cause of pneumonia among patients hospitalized in the United States at the current CLSI breakpoint criteria (MIC, ≤4/4 μg/ml).